Table 1 Baseline Characteristics
|  | Total (n = 1144) | ICS User (n = 478) | ICS nonuser (n = 560) | P-value |
|---|---|---|---|---|
Age | 68.1 ± 7.9 | 68.2 ± 7.9 | 68.2 ± 7.9 | 0.26 |
Male | 1057(92.4) | 439(91.8) | 520(92.9) | 0.13 |
Smoking status | Â | Â | Â | 0.80 |
 Current smoker | 348(30.4) | 147(30.8) | 168(30) |  |
 Ex-smoker | 700(61.2) | 295(61.7) | 340(60.7) |  |
 Non-smokera | 80(7.0) | 31(6.5) | 45(8.0) |  |
 Pack-years | 42.5 ± 25.1 | 43.2 ± 25.3 | 41.3 ± 24.3 | 0.26 |
BMI | 23.4 ± 10.3 | 23.0 ± 3.4 | 23.0 ± 14.4 | 0.78 |
SGRQ | 28.6 ± 17.0 | 33.4 ± 18.7 | 25.9 ± 15.5 | < 0.01 |
CAT | 14.2 ± 7.9 | 16.2 ± 7.9 | 12.9 ± 7.5 | < 0.01 |
mMRC | 1.4 ± 0.9 | 1.6 ± 0.9 | 1.2 ± 0.9 | < 0.01 |
FVC measured, L | 3.21 ± 0.82 | 3.03 ± 0.79 | 3.30 ± 0.79 | < 0.01 |
Post-BD FEV1, L | 1.67 ± 0.58 | 1.49 ± 0.54 | 1.75 ± 0.55 | < 0.01 |
Post-BD FEV1, % predicted | 61.37 ± 19.2 | 55.86 ± 19.12 | 63.38 ± 16.90 | < 0.01 |
Post-BD FEV1/FVC ratio | 50.88 ± 12.07 | 47.91 ± 12.25 | 52.3 ± 11.39 | < 0.01 |
Bronchodilator response | Â | Â | Â | 0.003 |
 None | 968(84.8) | 392(82) | 486(87.3) |  |
 BDR > 12% and 200 ml (FEV1) | 144(12.6) | 66(13.8) | 65(11.7) |  |
 BDR > 15% and 400 ml (FEV1) (Spanish ACO) | 29(2.5) | 20(4.2) | 6(1.1) |  |
DLco, % predicted | 75.36 ± 30.32 | 73.92 ± 23.99 | 75.52 ± 36.12 | 0.45 |
Asthma | 382(33.4) | 205(42.9) | 166(29.6) | < 0.001 |
Serum eosinophils cells/μlb | 179(102–302) | 179(108-328) | 178(97–280) | 0.16 |
Eosinophils > 300 cells/μl n (%) | 214(18.7) | 99(20.7) | 95(17.0) | 0.038 |
Exacerbation frequency, events/person-year | 0.44 ± 1.61 | 0.60 ± 1.65 | 0.33 ± 1.64 | < 0.01 |
 0 | 909(81.2) | 354(75.2) | 470(85.0) | < 0.001 |
 1 | 115(10.3) | 57(12.1) | 51(9.2) |  |
  ≥ 2 | 96(8.6) | 60(12.7) | 32(5.8) |  |
GOLD group |  |  |  | < 0.01 |
 A | 293(25.6) | 76(15.9) | 179(32.0) |  |
 B | 680(59.4) | 309(64.6) | 322(57.5) |  |
 C | 26(2.3) | 8(1.7) | 15(2.7) |  |
 D | 115(10.1) | 77(16.1) | 36(6.4) |  |